Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and iBiopsy®, our AI-powered software as medical device help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.
Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME), is part of the Enternext® PEA-PME 150 index and has been awarded the Euronext European Rising Tech label. For more information: www.mediantechnologies.com
Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME), is part of the Enternext® PEA-PME 150 index and has been awarded the Euronext European Rising Tech label. For more information: www.mediantechnologies.com
Location: France
Employees: 201-500
Total raised: $61.13M
Founded date: 2002
Investors 4
| Date | Name | Website |
| - | Auriga Par... | auriga.vc |
| - | Omega Fund... | omegafunds... |
| - | Idinvest P... | idinvest.c... |
| - | Abingworth... | abingworth... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 28.10.2025 | - | $22.22M | European I... |
| 19.12.2019 | - | $38.91M | - |
Mentions in press and media 7
| Date | Title | Description |
| 28.10.2025 | Median Technologies: €19 Million EIB Financing Raised To Boost AI-Enabled Cancer Diagnosis Platform | Median Technologies announced that it has received a €19 million payment under the first tranche of its new financing agreement with the European Investment Bank (EIB), executed July 11, 2025 and representing the initial drawdown of a facil... |
| 11.02.2025 | HeartcoR Solutions Names Healthcare and Pharma Industry Veteran Ciaran Cooper as CEO | HeartcoR Solutions Names Healthcare and Pharma Industry Veteran Ciaran Cooper as CEO. Cooper brings over 30 years' experience in medical device, clinical research, and pharmaceutical expertise to growing ECG core lab SCHAUMBURG, Ill. , Feb.... |
| 19.07.2023 | Daily AI Roundup: Biggest Machine Learning, Robotic And Automation Updates 19th July 2023 | This is our AI Daily Roundup . We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in artificial intelligence (AI), Machine Learning, Robotic Process Automation, Fintech, and human-s... |
| 18.07.2023 | Median Technologies Announces Onboarding of All Academic Sites Involved in the Pivotal Validation Plan for iBiopsy | Median Technologies (ALMDT) announces that the Company has officially commenced operations with all investigator sites participating in the pivotal validation plan for its iBiopsy Lung Cancer Screening (LCS) AI/ML tech-based CADe/CADx Softw... |
| 21.10.2021 | Median Technologies : Half-year financial report 2021 | Half-Year Financial Report June 30, 2021 Median Technologies SA This is a free translation into English of the Financial Report issued in French and it is provided solely for the convenience of English-speaking users. 1. PRESENTATION OF THE... |
| 06.09.2021 | Median Technologies : announces outstanding performance for its iBiopsy® Lung Cancer Screening CADx to accurately characterize malignant vs benign lung nodules based on a large-scale patient cohort | Press release - For immediate release September 06, 2021 - 05:45 pm CEST Median Technologies announces outstanding performance for its iBiopsy® Lung Cancer Screening CADx1 to accurately characterize malignant vs benign lung nodules based on... |
| 08.07.2021 | Median Technologies : rsquo; business continues to grow at a steady pace in the first half of 2021 (unaudited figures) | Press release - For immediate release - 5:45 pm CEST Median Technologies' business continues to grow at a steady pace in the first half of 2021 (unaudited figures) 71% increase in half-year revenue to €10.1m from €5.9m in H1 2020, a record ... |